H World Group Ltd shares climbed 8.1% to $45.26 on Monday after the company reported second-quarter results that topped Wall Street expectations and raised its FY26 sales guidance. The company posted quarterly earnings of 78 cents per share, above the analyst consensus estimate of 70 cents, and quarterly sales of $1.050 billion, ahead of the $982.800 million consensus estimate. The move came in a weaker broader market session, with U.S. stocks lower and the Dow Jones index down more than 100 points. Other notable gainers included Anbio Biotechnology, which jumped 50.5% to $13.15; OmniAb Inc, up 20.7% to $4.08 after lifting its FY26 cash and cash equivalent guidance and announcing a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program; and argenx SE - ADR, which rose 13.8% to $969.54 after saying topline results from the ALKIVIA Phase 3 study (late-stage clinical trial) met the primary endpoint. Cerebras Systems Inc gained 12.5% to $246.41, Angel Studios Inc added 10.5% to $4.83, and Mesoblast Ltd rose 9.3% to $17.05 after completing patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain. Swarmer Inc advanced 8.8% to $45.28, Almonty Industries Inc rose 8% to $16.29 after unveiling a $300 million share repurchase program, and Diana Shipping Inc gained 7.3% to $2.66 after withdrawing its Genco acquisition offer. Semtech Corp climbed 6.8% to $149.94, Capricor Therapeutics Inc rose 6% to $7.05, Credo Technology Group Holding Ltd gained 5.3% to $273.72, and Ocular Therapeutix Inc added 5.1% to $10.55.